At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.
Drug: Abidol hydrochloride
0.2g once, 3 times a day,two weeks
Drug: Abidol Hydrochloride combined with Interferon atomization
Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
Inclusion Criteria:
1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation
of viral pneumonia.
Exclusion Criteria:
1. Patients who meet any of the contraindications in the experimental drug labeling
2. Patients who do not want to participate in this clinical study
Department and Institute of Infectious Disease
Wuhan, Hubei, China
Investigator: Qin Ning, professor
qning@vip.sina.com
Qing Ning, Professor
+8613971521450
qning@vip.sina.com
Meifang Han, Professor
+8613986093605
mfhan@foxmail.com